Skip to main content
. Author manuscript; available in PMC: 2008 May 29.
Published in final edited form as: Endocrinology. 2006 Oct 12;148(1):218–231. doi: 10.1210/en.2006-1120

Fig. 6.

Fig. 6

Estrogen modulation of MMP-7 processing. A, Total homogenates of estrogen-depleted (SFM) or estrogen-treated cells (Est) were fractionated by gel electrophoresis and immunoprecipitated (IP) with the MMP-7 B-2 or with the MMP-7 F-12 antibodies and immunoblotted (IB) with the anti-GPP130 antibody. B–D, Estrogen-depleted or estrogen-treated cells were cotreated with tunicamycin (B, tun; 10 μg/ml for 72 h), brefeldin-A (C, Bre; 10 μM for 120 min), or monensin (D, Mon; 10 μM for 150 min). Total homogenates were fractionated by gel electrophoresis and immunoblotted with the anti-MMP-7 F-12 antibody. Parallel fractions were immunoblotted with the anti-GAPDH antibody. The experiments were repeated three times with similar trends.